For: | Rochoń J, Kalinowski P, Szymanek-Majchrzak K, Grąt M. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World J Gastroenterol 2024; 30(23): 2964-2980 [PMID: PMC11212696 DOI: 10.3748/wjg.v30.i23.2964] |
---|---|
URL: | https://www.wjgnet.com/2220-3249/full/v30/i23/2964.htm |
Number | Citing Articles |
1 |
Yanqiu Li, Bingbing Zhu, Ke Shi, Yu Lu, Xuanwei Zeng, Yongqi Li, Qun Zhang, Ying Feng, Xianbo Wang. Advances in intrahepatic and extrahepatic vascular dysregulations in cirrhotic portal hypertension. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1515400
|
2 |
Chia‐Chih Kuo, Min‐Hsiang Chuang, Chun‐Hsien Li, Ya‐Wen Tsai, Po‐Yu Huang, Hsing‐Tao Kuo, Chih‐Cheng Lai. Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes. Alimentary Pharmacology & Therapeutics 2025; doi: 10.1111/apt.18502
|
3 |
Li Lin, Shaowei Xiang, Yuan Chen, Yan Liu, Dingwen Shen, Xiaoping Yu, Zhe Wu, Yanling Sun, Kequan Chen, Jia Luo, Guilai Wei, Zhiguo Wang, Zhifeng Ning. Gut microbiota: Implications in pathogenesis and therapy to cardiovascular disease (Review). Experimental and Therapeutic Medicine 2024; 28(5) doi: 10.3892/etm.2024.12716
|
4 |
Merve Guney-Coskun, Metin Basaranoglu. Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy. World Journal of Gastroenterology 2024; 30(43): 4682-4688 doi: 10.3748/wjg.v30.i43.4682
|
5 |
Andrzej S Tarnawski. Editor-in-Chief articles of choice and comments from January to June 2024. World Journal of Gastroenterology 2024; 30(34): 3875-3882 doi: 10.3748/wjg.v30.i34.3875
|
6 |
Chun-Han Cheng, Wen-Rui Hao, Tzu-Hurng Cheng. Role of intestinal glucagon-like peptide-1 in hypoglycemia response impairment in type 1 diabetes. World Journal of Diabetes 2024; 15(11): 2237-2241 doi: 10.4239/wjd.v15.i11.2237
|
7 |
Ioannis Ilias, Lina Zabuliene, Manfredi Rizzo. GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks. Frontiers in Clinical Diabetes and Healthcare 2025; 5 doi: 10.3389/fcdhc.2024.1530811
|